Clinical updates, including trial initiations, enrollment status and data readouts and publications: Altimmune, Cstone, Everest, Ligand, Oncolys, Oncopeptides, Roche, Satsuma.

While privately held Levo Therapeutics Inc.’s phase III study of LV-101 (intranasal carbetocin) for treating Prader-Willi syndrome (PWS) failed to meet its primary outcome measurements, the company’s CEO told Bioworld the first secondary endpoint showed a statistical significance that raised her hopes the FDA might approve the selective oxytocin-receptor agonist for the indication.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Bioaegis, Boehringer, Dicerna, Idorsia, Levo, Medicinova, Nordic, Novartis, Personalized Stem Cells, Precigen, Rafael, Tessa.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Algernon, Axcella, Biontech, Clovis, Cytodyn, Elios, Emmaus, Fosun, Hepion, KBP, Modag, Novavax, Palatin, Pfizer.

Senhwa Biosciences Inc., of Taipei, Taiwan, said casein kinase 2 (CK2) is the right target to aim at when developing a COVID-19 therapeutic treatment. The company’s silmitasertib is the only clinical-stage inhibitor of CK2, a kinase recently identified by researchers as being hijacked by SARS-CoV-2.

With Glaxosmithkline plc (GSK) having sailed through an FDA advisory panel meeting July 14 centered on its belantamab mafodotin (belantamab), an antibody-drug conjugate (ADC) for multiple myeloma (MM), others in the B-cell maturation antigen (BCMA) space such as Legend Biotech Corp. are further piquing Wall Street’s interest.